Marksans Pharma Limited has recommended a final dividend of ₹0.90 per equity share of face value ₹1 each for the financial year ended March 31, 2026, as approved by its Board of Directors at a meeting held on May 26, 2026. The company simultaneously submitted its unaudited financial results for the quarter ended June 30, 2026 to the NSE on August 12, 2026, marking a dual disclosure event for investors tracking the mid-cap pharmaceutical manufacturer.

Dividend Details

The declared final dividend of ₹0.90 per share represents a 12.5% increase over the ₹0.80 per share paid in FY2025 and a 50% jump from the ₹0.60 per share declared in FY2024. With market price data unavailable at the time of this report, investors should calculate the dividend yield against the prevailing market price to assess income return. The dividend is subject to applicable tax deductions at source as per current Income Tax regulations.

Dividend Growth Trajectory

Marksans Pharma's dividend history reveals a sustained and sharply accelerating payout trend over the past decade. The progression underscores a consistent commitment to shareholder returns alongside business expansion:

From FY2017 to FY2026, the annual dividend per share has grown 18 times over, reflecting the company's improving cash generation capacity. Notably, no dividend was declared for FY2021, likely a consequence of pandemic-era capital conservation. Since FY2022, however, the company has raised its payout every single year without exception, compounding at a significant rate.

Company Background

Marksans Pharma Limited is a Mumbai-headquartered pharmaceutical company focused on finished dosage formulations, with a significant presence in regulated markets including the United States, United Kingdom, Europe, and Australia. The company operates manufacturing facilities compliant with international regulatory standards and derives a substantial portion of its revenue from generic over-the-counter and prescription products exported to these markets. It is listed on both the NSE and BSE under the symbol MARKSANS with ISIN INE750C01026.

Q1 FY2027 Results Filed

Alongside the dividend announcement context, Marksans Pharma has filed its unaudited financial results for the quarter ended June 30, 2026 with the NSE. The filing, submitted on August 12, 2026, marks the first quarterly disclosure for the new financial year and will provide investors with early visibility into revenue, EBITDA, and profitability trends following a year in which the company raised its dividend payout materially.

What This Means for Investors

The unbroken dividend growth streak since FY2022 signals management confidence in the company's recurring free cash flow. For income-focused investors, the ₹0.90 per share payout on a ₹1 face value share translates to a 90% dividend on face value. Investors should track the record date announcement, which is yet to be published on the NSE platform, to determine eligibility for the current payout. The Q1 FY27 results filing will be a key near-term data point to assess whether earnings momentum is keeping pace with the rising dividend commitment.